Sevuparin and hepcidin

Compelling data, presented at the European Hematology Association Congress (EHA) in June 2023, demonstrates sevuparin’s potential to treat anemia related to chronic diseases. These data show sevuparin’s ability to potently suppress hepcidin, thereby reducing the signaling which plays a key role in restricting the body’s access to iron for vital physiological processes such as the formation of hemoglobin and red blood cells.